The short version
- Why people research itMitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
- What the evidence isSmall randomized trials exist and are genuinely encouraging in a few conditions — fibromyalgia (small crossover trials reporting reduced pain) and Crohn's disease (small pilots reporting endoscopic improvement).
- What to watchOpioid withdrawal symptoms if opioids are in your system.
How Low Dose Naltrexone works
And there are two competing mechanistic accounts of how that could work. They are not variations on a theme; they involve different receptors on different cells, and only one of them requires the opioid system at all.
Account one: transient blockade, compensatory rebound. Naltrexone is a competitive antagonist at mu, kappa and delta opioid receptors. The card gives about 4 hours for the parent compound.
- Oral
On the goal map: Neuroinflammation & membrane integrity (Focus, memory & cognition)
Research on Low Dose Naltrexone7 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Small positive trials in fibromyalgia and Crohn's; the wider claims outrun the data.
Human clinical evidence
With solid trial data.
Small randomized trials exist and are genuinely encouraging in a few conditions — fibromyalgia (small crossover trials reporting reduced pain) and Crohn's disease (small pilots reporting endoscopic improvement). A Cochrane review of LDN in Crohn's concluded the evidence was insufficient.
Small, single-center, short. This is a promising signal that has never been funded to a definitive trial, largely because the drug is generic and nobody stands to profit from the answer.
Correlative data
Substantial real-world use in chronic pain and autoimmune conditions, largely driven by patient communities and a small number of prescribing clinicians. Vivid dreams and initial sleep disturbance are the common reports.
The interaction that matters is absolute: it blocks opioid analgesia, so it is incompatible with opioid pain management and dangerous around surgery if not disclosed.
How the mechanism reads
Two proposed mechanisms, and they are different. First, transient opioid receptor blockade causes rebound upregulation of endogenous endorphins and receptors.
MechanisticSecond, and probably more important for the inflammatory conditions: naltrexone antagonizes Toll-like receptor 4 on microglia, damping neuroinflammation. This mechanism is not opioid-mediated at all — it works with the non-opioid stereoisomer — which is why it can plausibly help conditions that have nothing to do with endorphins.
Mechanistic
Sources
- Due Bruun K, et al. Lancet Rheumatology 2024 · PMID 38258677
- Vatvani AD, et al. Korean Journal of Pain 2024 · PMID 39344363
- Partridge S, et al. Heliyon 2023 · PMID 37206027
- Gabr MM, et al. Interaction of Opioids with TLR4-Mechanisms and Ramifications. Cancers (Basel) 2021 · PMID 34771442
- Kučić N, et al. Immunometabolic Modulatory Role of Naltrexone in BV-2 Microglia Cells. International Journal of Molecular Sciences 2021 · PMID 34445130
- Mustafa S, et al. One immune system plays many parts: The dynamic role of the immune system in chronic pain and opioid pharmacology. Neuropharmacology 2023 · PMID 36775098
- Bruun KD, et al. Trials 2021 · PMID 34781989
Low Dose Naltrexone safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Taking opioid painkillers or being opioid dependent, since it would precipitate withdrawal.
- Acute hepatitis or liver failure.
- Pregnancy or breastfeeding, as naltrexone crosses into the fetus and milk.
- Expecting opioid pain relief after surgery.
What’s expected
- Vivid dreams and light sleep early on.
- Headache or mild stomach upset.
- The proposed mechanism is rebound endorphin release and microglial TLR4 antagonism.
Watch for
- Opioid withdrawal symptoms if opioids are in your system.
- Persistent insomnia or agitation.
- Skin yellowing with pale stool, a liver sign.
Labs that tell you it’s working
- hs-CRP: the neuroinflammation claim should show in systemic inflammation.
- Comprehensive Metabolic Panel: liver enzymes, as naltrexone is hepatically processed.
- TNF-Alpha (Tumor Necrosis Factor): a microglia-linked cytokine in the proposed mechanism.
Naltrexone below its licensed exposure: transient opioid receptor blockade and microglial TLR4 antagonism; opioid interaction is the key hazard. PMID 38258677 PMID 39344363 PMID 37206027
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Low Dose Naltrexone FAQ4 common questions
- Is Low Dose Naltrexone approved for human use?
- No. Low Dose Naltrexone is a research compound.
- What is Low Dose Naltrexone researched for?
- Mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
- Which labs show whether it's doing anything?
- hs-CRP; Comprehensive Metabolic Panel; TNF-Alpha: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Low Dose Naltrexone: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



